back

Secukinumab (new indication: hidradenitis suppurativa (HS) (acne inversa))

 

Subject:

  • Active Substance: Secukinumab
  • Name: Cosentyx®
  • Therapeutic area: Hidradenitis suppurativa (HS)
  • Pharmaceutical company: Novartis Pharma GmbH 

 

Time table:

  • Start: 15.06.2023
  • Publication of assessment: 15.09.2023
  • End of public hearing: 06.10.2023
  • Final decision by G-BA: beginning of December 2023

 

Comparative therapy:

  • Adalimumab